Zydus Receives Marketing Nod For Cancer Treatment Product

Zydus Lifesciences Ltd stated that the Mexican regulatory authority has approved the marketing of Mamitra, a Trastuzumab biosimilar for treating different cancer types. Mamitra is utilized for treating breast cancer as well as advanced stomach cancer. The company observed that breast cancer is now the most commonly diagnosed cancer in Mexico, surpassing prostate and colorectal cancers.

"The approval of Mamitra in Mexico allows us to expand the reach of our biosimilar portfolio to newer markets and enable access to affordable life-saving therapies, particularly in oncology," said Dr Sharvil Patel, managing director of Zydus.

The drug can now be sold in various potencies of 150 mg and 440 mg, following approval from COFEPRIS.

The research team at Zydus Research Centre (ZRC) internally developed the Trastuzumab biosimilar, which was released in India in 2016 as Vivitra. According to the company, around 100,000 patients have received treatment with the therapy since it was introduced.

Zydus Lifesciences Limited, previously named Cadila Healthcare Limited, is an Indian multinational pharmaceutical company based in Ahmedabad, focusing mainly on producing generic drugs.

Zydus Cadila develops and manufactures a wide variety of pharmaceuticals, diagnostics, herbal products, skincare products, and other OTC products in India through twenty-five pharmaceutical production operations.